Gentium S.p.A. (ADR)  

(Public, OTCMKTS:GENTY)   Watch this stock  
Find more results for Salvatore Ferro
Delayed:   3:29PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 7.26 - 59.25
Open     -
Vol / Avg. 0.00/6,528.00
Mkt cap 872.64M
P/E 108.60
Div/yield     -
EPS 0.52
Shares     -
Beta 1.58
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 22.92% 2.67%
Operating margin 24.15% 2.45%
EBITD margin - 7.47%
Return on average assets 29.28% 2.76%
Return on average equity 40.91% 4.10%
Employees 77 -
CDP Score - -


Piazza XX Settembre, 2
+39-31-5373200 (Phone)
+39-031-385241 (Fax)

Website links


Gentium SpA is a biopharmaceutical company focused on the development and manufacture of its product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded deoxyribonucleic acid (DNA) extracted from pig intestines. The Company’s development of defibrotide has been focused on the treatment and prevention of a disease called hepatic veno-occlusive disease ( VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. In February 2014, Jazz Pharmaceuticals PLC acquired the 98% interest in Gentium SpA (Gentium).

Officers and directors

Khalid Islam Chairman of the Board, Chief Executive Officer, Interim Scientific Director
Age: 59
Salvatore Calabrese Chief Financial Officer, Chief Operating Officer
Age: 44
Carin Heringa Senior Vice President, Scientific Director
Age: 52
Marco Maria Brughera Director
Age: 59
Laura Ferro Ph.D. Director
Age: 62
Gigliola Bertoglio CPA Independent Director
Age: 79
Bobby W. Sandage Jr., Ph.D. Independent Director
Age: 60
Elmar J Schnee Independent Director
Age: 56